Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new ...
NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...
Zacks Investment Research on MSN
NTRA's Signatera secures PMDA approval for MRD testing in CRC in Japan
Natera NTRA recently announced that Signatera has received PMDA approval in Japan for use in colorectal cancer (CRC) patients ...
With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring ...
Natera recently announced that its Signatera minimal residual disease (MRD) test received approval from Japan’s ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients ...
Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, ...
U.S. Minimal Residual Disease Testing Market is projected to reach USD 2.37 Billion by 2035, while Europe is expected to ...
Earlier blood-test detection could help identify pancreatic cancer patients who need more aggressive treatment, an expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results